2022
Interplay of Lymphocytes with the Intestinal Microbiota in Children with Nonalcoholic Fatty Liver Disease
Liang T, Li D, Zunong J, Li M, Amaerjiang N, Xiao H, Khattab N, Vermund S, Hu Y. Interplay of Lymphocytes with the Intestinal Microbiota in Children with Nonalcoholic Fatty Liver Disease. Nutrients 2022, 14: 4641. PMID: 36364902, PMCID: PMC9657134, DOI: 10.3390/nu14214641.Peer-Reviewed Original ResearchConceptsNonalcoholic fatty liver diseaseFatty liver diseaseHigher lymphocyte countsLymphocyte countGut microbiotaLiver diseaseHealthy childrenGut microbiota dysbiosisEffect of lymphocytesProinflammatory bacteriaMicrobiota dysbiosisRisk factorsIntestinal microbiotaAbundance of BacteroidetesLymphocytesMicrobiotaChildrenOpportunistic pathogenDiseaseCountMetagenomic sequencingLow numberHigher numberDysbiosisGroup
2009
Predictors of Suboptimal Virologic Response to Highly Active Antiretroviral Therapy Among Human Immunodeficiency Virus–Infected Adolescents: Analyses of the Reaching for Excellence in Adolescent Care and Health (REACH) Project
Ding H, Wilson CM, Modjarrad K, McGwin G, Tang J, Vermund SH. Predictors of Suboptimal Virologic Response to Highly Active Antiretroviral Therapy Among Human Immunodeficiency Virus–Infected Adolescents: Analyses of the Reaching for Excellence in Adolescent Care and Health (REACH) Project. JAMA Pediatrics 2009, 163: 1100-1105. PMID: 19996046, PMCID: PMC3739292, DOI: 10.1001/archpediatrics.2009.204.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAntiretroviral Therapy, Highly ActiveCD4 Lymphocyte CountChi-Square DistributionFemaleHIV InfectionsHumansInterviews as TopicLogistic ModelsMalePatient CompliancePredictive Value of TestsPrevalenceProspective StudiesStatistics, NonparametricTreatment OutcomeUnited StatesViral LoadYoung AdultConceptsHuman immunodeficiency virus-infected adolescentsSuboptimal virologic responsePoor virologic responseVirologic responseActive antiretroviral therapyAntiretroviral therapyVirologic suppressionMultivariable logistic regression modelDual antiretroviral therapyInitiation of HAARTSuboptimal antiretroviral therapyAge-specific interventionsAcademic medical centerLogistic regression modelsCohort studyLymphocyte countViral loadEcho findingsAdequate adherenceTherapeutic failureBiopsychosocial predictorsHAARTMedical CenterAdolescent careConsecutive visits
2007
Complete Blood Cell Count as a Surrogate CD4 Cell Marker for HIV Monitoring in Resource-Limited Settings
Chen RY, Westfall AO, Hardin JM, Miller-Hardwick C, Stringer JS, Raper JL, Vermund SH, Gotuzzo E, Allison J, Saag MS. Complete Blood Cell Count as a Surrogate CD4 Cell Marker for HIV Monitoring in Resource-Limited Settings. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2007, 44: 525-530. PMID: 17259910, DOI: 10.1097/qai.0b013e318032385e.Peer-Reviewed Original ResearchConceptsBirmingham Veterans Affairs Medical CenterTotal lymphocyte countCells/microLCD4 countVeterans Affairs Medical CenterComplete blood cell countAntiretroviral treatment statusLow CD4 cellsBody mass indexBlood cell countCells/Receiver operator characteristic curveResource limited settingsObservational databaseResource-limited settingsCD4 cellsLymphocyte count
1998
Analysis of Intercurrent Human Immunodeficiency Virus Type 1 Infections in Phase I and II Trials of Candidate AIDS Vaccines
Graham B, McElrath M, Connor R, Schwartz D, Gorse G, Keefer M, Mulligan M, Matthews T, Wolinsky S, Montefiori D, Vermund S, Lambert J, Corey L, Belshe R, Dolin R, Wright P, Korber B, Wolff M, Fast P, Group A. Analysis of Intercurrent Human Immunodeficiency Virus Type 1 Infections in Phase I and II Trials of Candidate AIDS Vaccines. The Journal Of Infectious Diseases 1998, 177: 310-309. PMID: 9466516, DOI: 10.1086/514209.Peer-Reviewed Original ResearchMeSH KeywordsAdultAIDS VaccinesAmino Acid SequenceCD4 Lymphocyte CountFemaleHIV AntibodiesHIV Envelope Protein gp120HIV InfectionsHIV-1HumansImmunity, ActiveIncidenceMaleMiddle AgedMolecular Sequence DataNeutralization TestsPeptide FragmentsRisk-TakingSequence AnalysisSubstance Abuse, IntravenousViral LoadConceptsHIV-1 infectionHuman immunodeficiency virus type 1 (HIV-1) infectionVirus type 1 infectionCandidate AIDS vaccinesType 1 infectionAIDS vaccinePhase IHigh-risk sexual exposureVaccine-induced immune responsesComplete immunization scheduleEarly clinical courseCD4 lymphocyte countIntravenous drug useV3 loop amino acid sequencesUninfected subjectsVaccine recipientsLymphocyte countClinical courseImmunization scheduleSexual exposureVirus loadImmune responseControl groupDrug useInfection
1997
Changes in total, CD4+, and CD8+ lymphocytes during pregnancy and 1 year postpartum in human immunodeficiency virus-infected women. The Women and Infants Transmission Study.
Tuomala RE, Kalish LA, Zorilla C, Fox H, Shearer W, Landay A, Vermund SH, Landesman S, Burns D. Changes in total, CD4+, and CD8+ lymphocytes during pregnancy and 1 year postpartum in human immunodeficiency virus-infected women. The Women and Infants Transmission Study. Obstetrics And Gynecology 1997, 89: 967-74. PMID: 9170476, DOI: 10.1016/s0029-7844(97)00129-4.Peer-Reviewed Original ResearchConceptsTotal lymphocyte countFirst postpartum yearLymphocyte countYear postpartumCell countCD8 percentagesNonpregnant cohortLymphocyte subsetsPostpartum yearHuman immunodeficiency virus-infected womenCD4/CD8 ratioInfants Transmission StudyHuman immunodeficiency virusImmediate postpartum periodCD4 percentMean CD4Nonpregnant HIVRelative CD4CD8 ratioAbsolute CD4Lymphocyte parametersNonpregnant womenImmunodeficiency virusPregnant womenPostpartum period
1991
Effect of zidovudine and Pneumocystis carinii pneumonia prophylaxis on progression of HIV-1 infection to AIDS
STUDY T, Graham N, Zeger S, Park L, Saah A, Phair J, Detels R, Vermund S, Ho M. Effect of zidovudine and Pneumocystis carinii pneumonia prophylaxis on progression of HIV-1 infection to AIDS. The Lancet 1991, 338: 265-269. PMID: 1677108, DOI: 10.1016/0140-6736(91)90414-k.Peer-Reviewed Original ResearchMeSH KeywordsAcquired Immunodeficiency SyndromeAerosolsCD4-Positive T-LymphocytesEvaluation Studies as TopicFollow-Up StudiesHIV SeropositivityHIV-1HumansLeukocyte CountMalePentamidinePneumonia, PneumocystisProspective StudiesRegression AnalysisRisk FactorsTime FactorsTrimethoprim, Sulfamethoxazole Drug CombinationZidovudineConceptsPneumocystis carinii pneumoniaEffect of zidovudineHIV-1 infectionPCP prophylaxisProbability of progressionLymphocytes/First episodePneumocystis carinii pneumonia prophylaxisHIV-1-infected individualsHIV-1-seropositive menMonth intervalsPrimary PCP prophylaxisEfficacy of zidovudinePresence of HIVRate of progressionMultivariate log-linear modelPneumonia prophylaxisMore CD4Primary prophylaxisZidovudine therapyLymphocyte countCarinii pneumoniaClinical trialsObservational studyProphylaxis